Prostate Cancer

Impact of Prior Treatments on Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: A Real-World Analysis in the United States. June 5, 2026

Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer. June 5, 2026

Stage-Specific Regulation of DNA Damage Repair by the Circadian Regulator, CRY1, in Prostate Cancer. June 5, 2026

Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial June 4, 2026

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer. June 4, 2026

Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis. June 4, 2026

USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer. June 4, 2026

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the Abstract June 3, 2026

Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States. June 3, 2026

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. June 3, 2026

A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues. June 5, 2026

Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer. June 5, 2026

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial - Beyond the Abstract June 4, 2026

One-Year Functional Satisfaction and Quality of Life Outcomes of Patients With a History of Radiotherapy With Artificial Urinary Sphincters. June 4, 2026

Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management. June 4, 2026

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer. June 4, 2026

Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancer. June 4, 2026

Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. June 3, 2026

One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. June 3, 2026

Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study. June 3, 2026

Page 1 of 1634